Lincoln Pharmaceuticals drugs has been awarded a patent for ‘An Arteether Injection for Treatment of Malaria’ by Government of India for antiprotozoal drug.
The drug is painless and offers quicker relief to the patients, Lincoln pharmaceutical company same.
In the times, this formulation, Arteether injection is available in market in 3ml and 2ml ampoules kind. At the time of injecting Arteether Injection to the patient by doctors, it’s terribly painful for a long time.
Patient can need to take this injection a minimum of for a amount of 3 days to manage the protozoal infection, company same in filing with BSE. The company’s R&D analysis team has developed a painless Injection with compressed indefinite quantity kind by reducing within drug material up to 50℅ volume. This new Arteether Injection developed by company is out there in 1 mil solely. as a result of this new innovation, patient can get quicker relief and painless.
“The results of this new “Arteether injection” is much better than the existing dosages are available within the market,” it added.
It same it expects to raise its exports of anti-malarial treatments by 70-80% because of the invention.
The company has received Patent No 258915 for the invention, it said.
Lincoln pharmaceutical company same the invention can facilitate it increase its presence in continent, already a giant marketplace for the corporate.
The majority of African countries use similar injections to manage protozoal infection.
The total anti-malarial market in African Countries are calculable Rs 586 metallic element, same the corporate.
Lincoln pharmaceutical company is commercialism nearly Rs 50 Crores anti-malarial merchandise to African countries.
“With introduction of this new “Arteether injection” in African countries, company expect to raise further Rs 35 large integer to Rs 40 large amount revenue within the upcoming years,” it said.
Note: Shares of the corporate were commerce at Rs 221.15 for each one on BSE, up 2.65 per cent from the previous shut.